688358 Chison Medical Technologies
- 32.40
- +0.41+1.28%
Chison Medical Technologies News
Southwest Securities released a research report on April 28 stating that it gave Xiangsheng Medical (688358.SH) a purchase rating, with a target price of 41.36 yuan. The main reasons for the rating include: 1) the 23-year performance was in line with expe
Southwest Securities released a research report on April 28 stating that it gave Xiangsheng Medical (688358.SH) a purchase rating, with a target price of 41.36 yuan. The main reasons for the rating include: 1) the 23-year performance was in line with expectations, and the profit side grew faster than the revenue side; 2) the overseas market fully built “SonoFamily”, and notebook ultrasound grew rapidly; 3) new products helped increase performance, and the products broadened application areas. (Mainichi Keizai Shimbun)
Chison Medical Technologies' (SHSE:688358) Profits May Not Reveal Underlying Issues
Chison Medical Technologies Co., Ltd. (SHSE:688358) just released a solid earnings report, and the stock displayed some strength. Despite this, our analysis suggests that there are some factors weake
Chison Medical Technologies Co., Ltd. (SHSE:688358) Surges 15%; Private Companies Who Own 50% Shares Profited Along With Insiders
Key Insights Chison Medical Technologies' significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public The top 2 shareholders own 64%
Guoxin Securities released a research report on April 23 stating that it gave Xiangsheng Medical (688358.SH) a purchase rating. The main reasons for the rating include: 1) the 2023 performance grew rapidly, and the first quarter of 2024 was affected by th
Guoxin Securities released a research report on April 23 stating that it gave Xiangsheng Medical (688358.SH) a purchase rating. The main reasons for the rating include: 1) the 2023 performance grew rapidly, and the first quarter of 2024 was affected by the high base for the same period in 2023; 2) the cost ratio declined and the net interest rate increased; 3) the volume of portable devices driven overseas business growth; 4) the layout of cutting-edge artificial intelligence technology, and the product is in the clinical trial stage. (Mainichi Keizai Shimbun)
Xiangsheng Medical (688358): Net profit due to mother increased 38% in 2023, overseas business grew rapidly
Results grew rapidly in 2023, and the first quarter of 2024 was affected by the high base for the same period in 2023. In 2023, the company achieved revenue of 484 million yuan (+27.04%) and net profit of 146 million yuan to mother (+
Xiangsheng Medical (688358): Performance is in line with expectations, notebook ultrasound is growing rapidly
Incident: The company released its 2023 annual report, achieved revenue of 480 million yuan (+27%), realized net profit of 150 million yuan (+38.4%), and realized deductions of 137 million yuan (+39.4%) from non-return to mother. At the same time, the company
Pharmaceutical and medical stocks fluctuated and rebounded | Tonghe Pharmaceutical and Wanfu Biotech rose more than 10%, while shares such as Yahuilong, Sannuo Biotech, Xiangsheng Healthcare, Betta Pharmaceuticals, Hanyu Pharmaceutical, and Eddy Pharmaceu
Pharmaceutical and medical stocks fluctuated and rebounded | Tonghe Pharmaceutical and Wanfu Biotech rose more than 10%, while shares such as Yahuilong, Sannuo Biotech, Xiangsheng Healthcare, Betta Pharmaceuticals, Hanyu Pharmaceutical, and Eddy Pharmaceuticals rose more than 5%.
Huafu Securities released a research report on April 21 stating that it gave Xiangsheng Medical (688358.SH) a purchase rating, with a target price of 43.01 yuan. The main reasons for the rating include: 1) the company released the 2023 annual report and t
Huafu Securities released a research report on April 21 stating that it gave Xiangsheng Medical (688358.SH) a purchase rating, with a target price of 43.01 yuan. The main reasons for the rating include: 1) the company released the 2023 annual report and the 2024 quarterly report; 2) the 2023 performance is in line with expectations, and the dividend ratio is impressive; 3) the overseas growth rate is excellent, the product structure continues to be optimized, and the continued high growth rate is expected; 4) As the research project continues, the introduction of new products will enable different clinical application scenarios. (Mainichi Keizai Shimbun)
Xiangsheng Medical (688358): Performance is in line with expectations, optimistic that overseas volumes will continue to grow at a high rate
Investment highlights: The company publishes the 2023 annual report and the 2024 quarterly report. In 2023, the company achieved revenue of 484 million yuan (+27.0%), net profit of 146 million yuan (+38.4%) to mother, deducted from mother
Xiangsheng Medical's share of overseas revenue reached a record high, driving positive revenue growth in 2023 with a dividend rate of over 60%
① Overseas markets were reduced by the impact of the epidemic in 2023 and resumed growth, which in turn led to an increase in annual performance. ② “The company's overseas market business layout is scattered, not concentrated in a specific region, and there are no detailed divisions in terms of revenue.”
Xiangsheng Medical (688358.SH): Net profit increased 38.39% year-on-year in 2023, and plans to pay 10 to 8 yuan
On April 18, Ge Longhui (688358.SH) announced its 2023 annual report. Operating revenue for the reporting period was 484 million yuan, up 27.04% year on year; net profit attributable to shareholders of listed companies was 146 million yuan, up 38.39% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 137 million yuan, up 39.39% year on year; basic earnings per share were 1.33 yuan. It is proposed to distribute a cash dividend of RMB 8 (tax included) for every 10 shares to all shareholders.
Express News | Xiangsheng Medical launches global ultrasound technology training center
Chison Medical Technologies Co., Ltd. (SHSE:688358) Stock Rockets 25% But Many Are Still Ignoring The Company
Those holding Chison Medical Technologies Co., Ltd. (SHSE:688358) shares would be relieved that the share price has rebounded 25% in the last thirty days, but it needs to keep going to repair the rece
Xiangsheng Medical (688358): Accelerate the expansion of overseas channels to achieve steady business growth
Investment highlights: Event: The company released its 2023 performance report. The company expects to achieve revenue of 490 million yuan (+29% year over year), achieve net profit of 155 million yuan (+47% year over year) in 2023, and achieve deduction from mother
Xiangsheng Medical (688358.SH) Performance Report: 2023 net profit of 155 million yuan, up 46.58% year on year
Gelonghui, Feb. 25丨Xiangsheng Medical (688358.SH) announced the 2023 Annual Results Report. During the reporting period, the company achieved operating income of 49,00287 million yuan, an increase of 28.67%; achieved net profit attributable to owners of the parent company of 155.1419 million yuan, an increase of 46.58% year on year; realized net profit attributable to owners of the parent company after deducting non-recurring profit and loss of 145.9032 million yuan, a year-on-year increase of 48.22%; basic earnings per share were 1.41 yuan, an increase of 50.00% year on year.
It's Down 26% But Chison Medical Technologies Co., Ltd. (SHSE:688358) Could Be Riskier Than It Looks
The Chison Medical Technologies Co., Ltd. (SHSE:688358) share price has fared very poorly over the last month, falling by a substantial 26%. Instead of being rewarded, shareholders who have already
Xiangsheng Medical (688358): An established manufacturer of AI superimposed portable ultrasound has embarked on a new route
Key investment points: AI enables the expansion of ultrasound application scenarios to achieve differentiated competition. The number of ultrasound examinations in China exceeds 2 billion times a year, ranking first among commonly used medical tests (such as X-ray, CT, endoscopy, magnetic resonance, etc.); sonographers
Chison Medical Technologies (SHSE:688358) Is Reinvesting At Lower Rates Of Return
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for? One common approach is to try and find a company with returns on capital employed
Xiangsheng Medical (688358.SH): SonoFamily products have generated revenue
Gelonghui, December 29丨Xiang Sheng Medical (688358.SH) said on the interactive platform that SonoFamily series products, including SonoMax, SonoAir, and SonoEye, are innovative achievements in the company's technical strength, and their disruptive changes will bring new diagnostic experiences to healthcare workers and patients. They have now been actively showcased at various exhibitions around the world, winning great attention from participating visitors and being deeply recognized by agents around the world. Currently, SonoFamily series products have generated revenue. For details, please pay attention to the relevant announcements publicly disclosed by the company.
Xiangsheng Medical (688358.SH): Currently, related ultrasound artificial intelligence products are in clinical trials
Glonghui December 22|Xiangsheng Medical (688358.SH) stated on an interactive platform that the company is the only ultrasound equipment manufacturer in the “China Ultrasound Medical Artificial Intelligence Alliance” (USAI for short). Xiangsheng Medical pioneered the field of ultrasound artificial intelligence technology. It has taken the lead in mastering core technologies such as artificial intelligence for four categories of breast ultrasound, dynamic multi-modal artificial intelligence, and artificial intelligence for carotid artery plaques stability/fragility, and has obtained a number of software copyrights and invention patents. Currently, related ultrasound artificial intelligence products are in clinical trials.
Analysis
Price Target
No Data
